Glial Cells
Introduction ```mermaid flowchart TD classDef gene fill:#0a1f0a,stroke:#4caf50 classDef protein fill:#0a1929,stroke:#2196f3 classDef disease fill:#2d0f0f,stroke:#e91e63 classDef pathway fill:#3e2200,stroke:#ff9800 classDef mechanism fill:#1a0a1f,stroke:#9c27b0 classDef therapeutic fill:#e0f2f1,stroke:#009688 Glial_Cells["Glial Cells"] -->|"involved_in"| Parkinson_s_Disease["Parkinson's Disease"] Glial_Cells["Glial Cells"] -->|"causes"| Neuronal_Damage["Neuronal Damage"] Glial_Cells["Glial Cells"] -->|"involved_in"| Neuroinflammation["Neuroinflammation"] Glial_Cells["Glial Cells"] ==>|"upregulates"| Proinflammatory_Cytokines["Proinflammatory Cytokines"] Glial_Cells["Glial Cells"] -->|"contributes_to"| Alzheimer_s_Disease["Alzheimer's Disease"] Glial_Cells["Glial Cells"] -->|"involved_in"| Alzheimer_s_Disease["Alzheimer's Disease"] Glial_Cells["Glial Cells"] -->|"mediates"| Gender_Differences_in_Neurodegeneration["Gender Differences in Neurodegeneration"] Glial_Cells["Glial Cells"] -->|"involved_in"| Synapse_Pathology["Synapse Pathology"] Glial_Cells["Glial Cells"] -->|"component_of"| Neurovascular_Unit["Neurovascular Unit"] Glial_Cells["Glial Cells"] -->|"mediates"| Neuroinflammation["Neuroinflammation"] Glial_Cells["Glial Cells"] -->|"contributes_to"| Parkinson_S_Disease["Parkinson'S Disease"] Glial_Cells["Glial Cells"] -->|"modulates"| Neurodegeneration["Neurodegeneration"] Glial_Cells["Glial Cells"] -->|"associated_with"| Neurodegeneration["Neurodegeneration"] Glial_Cells["Gl
...
Glial Cells
Introduction
Mermaid diagram (expand to render)
<table class="infobox infobox-cell"> <tr> <th class="infobox-header" colspan="2">Glial Cells</th> </tr> <tr> <td class="label">Name</td> <td><strong>Glial Cells</strong></td> </tr> <tr> <td class="label">Type</td> <td>Cell Type</td> </tr> </table>
Glial cells (neuroglia) are non-neuronal cells that constitute approximately 50% of the human brain volume. Once considered mere support cells, astrocytes, oligodendrocytes, and microglia are now recognized as active participants in neural circuit function, synaptic transmission, and brain homeostasis [@allen2009].
Types of Glial Cells
Astrocytes The most abundant glial cell type in the CNS, astrocytes outnumber neurons by approximately 5:1 in human cortex.
Characteristics:
Star-shaped cells with multiple branching processes
Express GFAP (glial fibrillary acidic protein)
Contact both blood vessels and neurons
Form the blood-brain barrier alongside endothelial cells
Functions:
Synaptic support : Provide metabolic support to neurons, recycle neurotransmitters
Ion homeostasis : Regulate extracellular potassium and calcium
Water balance : Aquaporin-4 channels for water transport
Neuroinflammation : Release cytokines and chemokines in response to injury
Oligodendrocytes (CNS) and Schwann Cells (PNS) Responsible for myelinating axons in the CNS and PNS respectively.
CNS Oligodendrocytes:
Each oligodendrocyte myelinates multiple axons (up to 50)
Express MBP (myelin basic protein) and PLP (proteolipid protein)
Form internodes with nodes of Ranvier for saltatory conduction
PNS Schwann Cells:
Myelinate single axons
Express P0 and PMP22 proteins
Support peripheral nerve regeneration
Microglia The resident immune cells of the brain, derived from yolk sac progenitors.
Characteristics:
Small cell bodies with ramified processes
Express IBA1 (ionized calcium-binding adapter molecule 1)
Constantly survey the brain parenchyma
Turn over slowly throughout life
Functions:
Immune surveillance : Phagocytose debris and pathogens
Synaptic pruning : Eliminate excess synapses during development
Neuroinflammation : Release pro-inflammatory cytokines when activated
Support neuronal health : Produce neurotrophic factors
Glial Cells in Neurodegenerative Diseases
Alzheimer's Disease Astrocytes:
Reactive astrocytes surround amyloid plaques
Lose normal functions ( glutamate recycling)
Contribute to neuroinflammation
Form astrocytic plaques (Aβ accumulation)
Microglia:
Chronic activation around plaques
Create neurotoxic inflammatory environment
TREM2 variants increase AD risk
Failed clearance of Aβ and tau
Oligodendrocytes:
Myelin degeneration precedes clinical symptoms
Vulnerable to oxidative stress
Loss contributes to white matter atrophy
Parkinson's Disease Astrocytes:
Reactive astrocytes in substantia nigra
Impaired dopamine metabolism
May spread α-synuclein pathology
Microglia:
Chronic activation in substantia nigra
NADPH oxidase-mediated oxidative stress
Contribute to dopaminergic neuron death
Oligodendrocytes:
Myelin abnormalities in PD brains
α-Synuclein accumulation in oligodendrocytes
Vulnerable to iron-induced oxidative stress
Amyotrophic Lateral Sclerosis (ALS) Astrocytes:
Loss of glutamate transporters (EAAT2)
Excitotoxicity due to glutamate accumulation
Non-cell autonomous toxicity to motor neurons
Microglia:
Activated in spinal cord and motor cortex
Pro-inflammatory cytokine release (TNF-α, IL-1β)
Mutant SOD1 in microglia contributes to disease
Oligodendrocytes:
Pre-motor neuron degeneration
Failed remyelination in progressive stages
Oligodendrocyte precursor cells fail to differentiate
Glial-Neuronal Interactions
Tripartite Synapse Astrocytic processes ensheath synapses, forming a tripartite synapse:
Pre-synaptic neuron
Post-synaptic neuron
Perisynaptic astrocyte
Astrocytes detect neurotransmitter release and modulate synaptic transmission.
Neurovascular Coupling Astrocytes regulate cerebral blood flow by:
Sensing neural activity through calcium signals
Releasing vasoactive substances (prostaglandins, epoxyeicosatrienoic acids)
Causing vasodilation of nearby arterioles
Gliotransmission Astrocytes release signaling molecules:
Glutamate (via vesicles)
D-serine (co-agonist for NMDA receptors)
ATP/adenosine (modulates synaptic plasticity)
Therapeutic Targets
Astrocyte-Targeted Therapies
EAAT2 modulators : Enhance glutamate uptake
A1 adenosine receptor antagonists : Block astrocyte-mediated toxicity
GFAP inhibitors : Reduce reactive astrogliosis
Microglia-Targeted Therapies
TREM2 agonists : Enhance phagocytosis
CD33 inhibitors : Reduce amyloid clearance blockade
Anti-inflammatory drugs : Modulate neuroinflammation
Oligodendrocyte-Targeted Therapies
Remyelination promoters : LINGO-1 antagonists
MBP stabilizers : Protect existing myelin
OPC recruitment : Enhance oligodendrocyte precursor differentiation
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Show full description